These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15663159)

  • 21. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
    Tubaro A; Puccini F; De Nunzio C
    Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostaglandin E2 and bethanechol in combination for treating detrusor underactivity.
    Dasgupta R
    BJU Int; 2004 Jul; 94(1):191-2. PubMed ID: 15217463
    [No Abstract]   [Full Text] [Related]  

  • 23. Re: botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity.
    Wein AJ
    J Urol; 2014 May; 191(5):1340-1. PubMed ID: 24745503
    [No Abstract]   [Full Text] [Related]  

  • 24. Botulinum toxin A for the Treatment of Overactive Bladder.
    Hsieh PF; Chiu HC; Chen KC; Chang CH; Chou EC
    Toxins (Basel); 2016 Feb; 8(3):. PubMed ID: 26938559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should we stop using botulinum neurotoxin type a in patients with neurogenic detrusor overactivity after development of secondary resistance?
    Pistolesi D; Giannarini G; Stampacchia G; Selli C
    Eur Urol; 2011 Oct; 60(4):872-3. PubMed ID: 21802198
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacological prevention of migraine.
    Fenstermacher N; Levin M; Ward T
    BMJ; 2011 Feb; 342():d583. PubMed ID: 21335409
    [No Abstract]   [Full Text] [Related]  

  • 27. Submucosal injections of botulinum toxin A in women with refractory idiopathic detrusor overactivity.
    Onyeka BA; Shetty A; Ilangovan K; Saxena A
    Int J Gynaecol Obstet; 2010 Jul; 110(1):68-9. PubMed ID: 20347085
    [No Abstract]   [Full Text] [Related]  

  • 28. Onabotulinum toxin injection in neurogenic detrusor overactivity: intradetrusor versus suburothelial.
    Burki JR; Hamid R
    Spinal Cord; 2013 Sep; 51(9):725. PubMed ID: 23774129
    [No Abstract]   [Full Text] [Related]  

  • 29. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
    Mouttalib S; Khan S; Castel-Lacanal E; Guillotreau J; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
    BJU Int; 2010 Dec; 106(11):1677-80. PubMed ID: 20590550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder.
    Ellsworth P; Travis M
    Urol Nurs; 2014; 34(4):165-71. PubMed ID: 25233617
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to ‘Onabotulinum toxin injection in neurogenic detrusor overactivity: intradetrusor versus suburothelial’.
    Krhut J; Samal V; Nemec D; Zvara P
    Spinal Cord; 2013 Sep; 51(9):726. PubMed ID: 23797569
    [No Abstract]   [Full Text] [Related]  

  • 32. Botulinum toxin injection for lower urinary tract dysfunction.
    Kuo YC; Kuo HC
    Int J Urol; 2013 Jan; 20(1):40-55. PubMed ID: 22571329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics.
    Kuo HC
    Urology; 2005 Jul; 66(1):94-8. PubMed ID: 15992869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of Botulinum Toxin in Urologic Diseases.
    Chermansky CJ; Chancellor MB
    Urology; 2016 May; 91():21-32. PubMed ID: 26777748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity.
    Conte A; Giannantoni A; Proietti S; Giovannozzi S; Fabbrini G; Rossi A; Porena M; Berardelli A
    Eur J Neurol; 2012 May; 19(5):725-32. PubMed ID: 22212295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurophysiology of micturition and pharmacotherapy of lower urinary tract dysfunction.
    Cerruto ; Pesce F; Artibani W
    Diabetes Nutr Metab; 2002 Feb; 15(1):28-41. PubMed ID: 11942736
    [No Abstract]   [Full Text] [Related]  

  • 37. Botulinum toxin for the lower urinary tract.
    Chuang YC; Kuo HC; Chancellor MB
    BJU Int; 2010 Apr; 105(8):1046-58. PubMed ID: 22299133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing therapy and management of neurogenic bladder.
    Ginsberg D
    Am J Manag Care; 2013; 19(10 Suppl):s197-204. PubMed ID: 24495241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence.
    Grosse J; Kramer G; Stöhrer M
    Eur Urol; 2005 May; 47(5):653-9. PubMed ID: 15826758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [INJECTION OF BOTULINUM TOXIN TYPE A IN THE BLADDER DETRUSOR AND SUBMUCOSA IN PATIENTS WITH OVERACTIVE BLADDER WITHOUT DETRUSOR OVERACTIVITY].
    Krivoborodov GG; Tur EI; Efremov NS
    Urologiia; 2015; (2):31-4. PubMed ID: 26237802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.